Articles Authored by staff reporter
Apollomics Completes SPAC Merger, Begins Public Trading on Nasdaq
The firm is developing therapies for MET-altered tumors and acute myeloid leukemia.
Ablaze Pharmaceuticals to Develop RayzeBio's GPC3-Targeted Radiotherapy
Ablaze will develop and commercialize the peptide drug candidate in China and surrounding regions.
In Brief This Week: Allarity Therapeutics, Immutep, Thermo Fisher Scientific
News items for the week of March 27, 2023.
EMA's CHMP Recommends BMS's Breyanzi as Second-Line Lymphoma Treatment
If approved in Europe, Breyanzi would compete with Gilead Sciences' CAR T-cell therapy Yescarta, which netted second-line LBCL approval in Europe last fall.
Exai Bio, Quantum Leap Healthcare Collaborative Expand Participation in RNA Liquid Biopsy Trial
The collaborators are using Exai's oncRNA-based liquid biopsy tech in predicting clinical outcomes and treatment response in the I-SPY 2 trial.
Omega Therapeutics, Roche Partner for Phase I/II Trial in MYC-Driven Hepatocellular Carcinoma
Roche will supply its anti-PD-L1 therapy atezolizumab for a combination trial with Omega's OTX-2002 in hepatocellular carcinoma and other MYC-driven tumors.
Merck Nabs Full FDA Approval for Keytruda in MSI-High, dMMR Solid Tumors
The conversion from accelerated to full approval marks the first time the FDA has granted full approval to an immunotherapy in a tumor-agnostic indication.
PDS Biotech to Begin Phase III Trial of Immunotherapy in HPV 16-Positive Head and Neck Cancer
The company is studying its HPV-targeted immunotherapy PDS0101 with Merck's Keytruda.
NCCN Adds Mirati Therapeutics' Krazati to Guidelines for KRAS-Mutant NSCLC With Brain Metastases
The guidelines suggest Krazati as a systemic therapy option for patients with KRAS G12C-mutant non-small cell lung cancer with central nervous system metastases.
European Commission Approves Libtayo in PD-L1-Positive Non-Small Cell Lung Cancer
The EC's approval is based on data from a Phase III trial showing a significant increase in overall survival and progression-free survival compared to placebo.